TRIM32 and cardiac hypertrophy: These results suggest that the mechanisms underlying the cardioprotective effect of TRIM32 on the pathological cardiac hypertrophy could plausibly be dependent on inhibiting the prolonged activation of the Akt-dependent signalling pathways.